Navigation Links
Synthetic Biologics Reports Third Quarter 2012 Financial Results
Date:11/14/2012

r the treatment of Acinetobacter infections and of our preclinical program for the development of a DNA-based therapy for the treatment of pulmonary arterial hypertension (PAH). Charges related to stock-based compensation were $116,000 and $238,000 for the three and nine months ended September 30, 2012, respectively, compared to $6,000 and $20,000 for the same periods in 2011.

Other income was $10,000 for the three months ended September 30, 2012, compared to other expense of $159,000 for the same period in 2011. Other income was $22,000 for the nine months ended September 30, 2012, compared to other expense of $1.7 million for the same period in 2011. Other expense for the nine months ended September 30, 2011 related to the estimated fair value of the warrants associated with the January 2011 and April 2011 financings, adjusted for the change in their fair value at September 30, 2012.

Cash at September 30, 2012 was $4.6 million compared to $6.7 million at December 31, 2011. As of October 31, 2012, we had approximately $14.2 million in cash.

About Synthetic Biologics, Inc.Synthetic Biologics is a biotechnology company focused on the development of product candidates for serious infections and diseases. Synthetic Biologics is developing a biologic for the prevention of C. diff infection, and a series of monoclonal antibodies (mAbs) for the treatment of serious infectious diseases, including Acinetobacter. The Company is also developing a synthetic DNA-based therapy for the treatment of pulmonary arterial hypertension (PAH). In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS, and designing a clinical development pathway for the treatment of amyotrophic lateral sclerosis (ALS). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

mAbLogix
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Synthetic Biologics to Acquire Clinical-Stage C. difficile Infectious Disease Program
2. Taming mavericks: Stanford researchers use synthetic magnetism to control light
3. Synthetic Biologics Completes $10.8 Million Private Placement Financing
4. Synthetic Biologics Announces $10.8 Million Financing
5. Synthetic Genomics Inc. Purchases Patent Portfolio from Febit Holding GmbH
6. Synthetic Biology Market is Expected to Reach USD 16.7 Billion Globally in 2018: Transparency Market Research
7. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
8. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
9. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
10. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman
11. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... OXFORD, England , May 22, 2013 ... inhaled, novel drug-only formulation of glycopyrronium bromide designed using ... speciality pharmaceutical company developing a portfolio of inhaled ... 2 clinical study with PSX1002 that will assess its ... range of doses in patients with moderate to severe ...
(Date:5/21/2013)... study led by George Washington University Professor Tianshu ... ice in small droplets is strongly size-dependent, an ... nanoscale. The formation of ice at the nanoscale ... answer also has important implications for climate research ... ice from supercooled water is generally initiated by ...
(Date:5/21/2013)... Smarter Security, Inc., provider of premium, ... that Genzyme, a Sanofi company and leading biotech company, ... for a multi-use facility in the United States. With ... buildings, this latest order underscores the satisfaction and success ... device improving doorway access control. , “We ...
(Date:5/21/2013)... Md. , May 21, 2013  MacroGenics, ... 1 study of margetuximab (MGAH22), an Fc-modified chimeric ... tumors expressing the HER2 oncoprotein," will be presented ... Society of Clinical Oncology during the Developmental Therapeutics ... 3 at 4:15 – 4:30 PM.  The presentation ...
Breaking Biology Technology:Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... A non-invasive blood,monitoring device that removes the need ... 2008 Kerrin Rennie Award for Excellence in Medical ... 24 September at the,Medical Technology Association of Australia ... CO-Oximeter from Masimo Corporation continuously,and non-invasively measures blood ...
... -, MONTVALE, N.J., Sept. 26 Memory,Pharmaceuticals Corp. ... completed,its Phase 1 multiple ascending dose study of R4996/MEM ... the fourth and final study,in the Company,s Phase 1 ... alpha-7 receptor being developed in collaboration with Roche.,Memory Pharmaceuticals ...
... a first, researchers at the University of Iowa and the ... cystic fibrosis (CF) that appears to closely mimic the disease ... the CF piglets and human newborns with CF suggest that ... and may also speed discovery of new treatments. The study ...
Cached Biology Technology:No Blood Needed Thanks to Innovative Medical Technology 2Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908 2Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908 3Researchers develop new model for cystic fibrosis 2
(Date:5/21/2013)... "place" is increasingly being considered in the management ... new resource that can help them recognize and ... places in their lives. , Place-Based Conservation: ... co-edited by the Pacific Northwest Research Station,s Linda ... to conservation. The book is published by Springer ...
(Date:5/21/2013)... method for delivering molecules into single, targeted cells ... technique could find applications in drug delivery, cell ... a technique used to deliver molecules into ... that are caused by exposing them to electric ... cell transfection. (Cell transfection is the introduction of ...
(Date:5/21/2013)... University of Illinois at Chicago College of Medicine will study ... -- its main energy source -- and how changes in ... new $2 million, 4-year grant from the National Heart, Lung ... it uses fuel for energy. These changes may play a ... different in men and women, says E. Douglas Lewandowski, director ...
Breaking Biology News(10 mins):Single-cell transfection tool enables added control for biological studies 2Do men's and women's hearts burn fuel differently? 2
... raged over whether organic compounds and tiny globules of ... 84001 were processed by living creatures from the Red ... scrutiny ever since. Scientists at the Carnegie Institution's Geophysical ... how material associated with carbonate globules was created using ...
... more than 100 people have been infected with the H5N1 ... the fact that the virus does not spread easily from ... biomedical puzzle. , Now, a study of cells in the ... cells of the system that makes it difficult for the ...
... North America, two types of invasive vines are growing ... populations and bird habitats. , The vines are pale ... to stem the growth of and their steady conquest ... Canada, Cornell University is teaming up with the U.S. ...
Cached Biology News:Relic of life in that Martian meteorite? A fresh look 2Cell barrier shows why bird flu not so easily spread among humans 2Cell barrier shows why bird flu not so easily spread among humans 3CU, USDA team to curb two invasive, poisonous vines 2CU, USDA team to curb two invasive, poisonous vines 3
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
...
...
Biology Products: